These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 3497612

  • 1. [The management of malignant ascites with a streptococcal preparation, OK-432: relation between the clinical effect and auto-tumor cell killing activity by OK-432-induced ascites-derived lymphocytes].
    Katano M, Yamamoto H, Mizoguchi T, Hidaka K, Hisatsugu T, Torisu M.
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2464-8. PubMed ID: 3497612
    [Abstract] [Full Text] [Related]

  • 2. [Management of malignant ascites by intraperitoneal injection of OK-432. Possible mechanism of the reduction of original tumor mass volume].
    Katano M, Mizoguchi T, Yamamoto H, Hisatsugu T, Torisu M.
    Nihon Geka Gakkai Zasshi; 1987 Dec; 88(12):1676-83. PubMed ID: 3447033
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients.
    Watanabe N, Niitsu Y, Yamauchi N, Neda H, Sone H, Urushizaki I, Yamamoto A, Nagamuta M, Sugawara Y.
    Immunopharmacol Immunotoxicol; 1988 Dec; 10(1):53-65. PubMed ID: 3361071
    [Abstract] [Full Text] [Related]

  • 13. Induction of tumor necrosis factor by administration of OK-432 in cancer patients.
    Kokunai I, Shimano T, Sekimoto K, Takeda T, Kobayashi T, Yayoi E, Yamamoto A, Mori T.
    J Clin Lab Immunol; 1986 Dec; 21(4):169-71. PubMed ID: 3560194
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Effect of malignant ascitic fluids and OK-432 on the induction of LAK activity in peripheral blood mononuclear cells of gynecological cancer patients].
    Kanaoka Y, Umesaki N.
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jun; 43(6):611-8. PubMed ID: 1856521
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Immunotherapy of gastric cancer].
    Kan N, Ohgaki K, Okino T, Nakanishi M, Nio Y, Inoue K, Tobe T.
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):755-62. PubMed ID: 3291771
    [Abstract] [Full Text] [Related]

  • 20. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
    Kan N, Hori T, Ohgaki K, Inamoto T, Kodama H, Tobe T.
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.